In a recent study, patients with psoriatic arthritis taking tofacitinib had a decrease in disease activity compared with placebo…
Search results for: psoriasis
Obesity & Rheumatic Disease
“Obesity is an inflammatory state, so it is in the landscape of the rheumatologist,” says Christopher Ritchlin, MD, MPH. And the more attention rheumatologists pay to obesity, the better…
FDA Update on Rituximab & Etanercept; Plus New ACP Gout Guideline
The FDA is considering an application for subcutaneous rituximab and has approved an application for etanercept to treat pediatric patients with plaque psoriasis…
2015 Treatment Recommendation Updates for Psoriatic Arthritis Address Comorbidities, New Medications
In May, the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) published its recommendations for the treatment of psoriatic arthritis (PsA).1 The updated recommendations represent advances in drug development and availability since previous recommendations published in 2009, as well changes in treatment paradigms and the importance of associated aspects of the disease.2…
Treating the Athlete: New Thoughts on How to Prevent & Treat Arthritis in Athletes & Raise Their Awareness
All athletes—amateur and professional—should understand their risks for developing injury-related arthritis. Rheumatologists and other physicians at the Hospital for Special Surgery in New York take a rapid approach to treating athletes, often considering intense physical therapy, innovative treatments and surgery much sooner than for the average patient—all to keep joints healthy and enable athletes to play for as long as possible…
Clinical Trial of Ixekizumab for Psoriatic Arthritis Shows Positive Results
A study found that ixekizumab decreases disease activity and increases physical function in biologic-naive patients with active psoriatic arthritis…
Adalimumab-atto, Biosimilar to Humira, Receives FDA Approval
Adalimumab-atto, a biosimilar to adalimumab (Humira), has been approved by the FDA to treat multiple autoimmune diseases…
FDA Approves Ustekinumab for Crohn’s Disease
(Reuters)—Johnson & Johnson says on Monday that the U.S. Food and Drug Administration approved the company’s psoriasis drug, ustekinumab (Stelara), for use in adults with Crohn’s disease. The drug is approved in the U.S. to treat plaque psoriasis and a type of arthritis associated with psoriasis. Crohn’s is a chronic inflammatory condition in the gastrointestinal…
FDA Approves Adalimumab-atto, a Biosimilar of Humira
WASHINGTON (Reuters)—The U.S. Food and Drug Administration on Friday approved a cheaper, biosimilar version of AbbVie’s top-selling arthritis drug, adalimumab (Humira). The drug, adalimumab-atto (Amjevita), is made by biotechnology company Amgen Inc. and was approved to treat rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, psoriasis and other conditions. Amjevita is the fourth biosimilar to be approved…
Express Scripts Tries to Rein in Pricey Inflammatory Drugs
NEW YORK (Reuters)—Express Scripts Holding, the largest manager of U.S. drug benefits, on Thursday launched a program aimed at tightening spending on drugs for pricey inflammatory conditions such as rheumatoid arthritis. It is the latest Express Scripts effort intended to reduce spending on prescription drugs, such as last week’s announcement of a diabetes program. Early…
- « Previous Page
- 1
- …
- 36
- 37
- 38
- 39
- 40
- …
- 55
- Next Page »